• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Elevated neutrophil-lymphocyte ratio associated with poor prognosis for head and neck cancer

byJake EngelandMichael Pratte
April 21, 2022
in Chronic Disease, Oncology, Surgery
Reading Time: 2 mins read
No difference in PET-CT surveillance versus planned neck dissection in advanced head and neck cancer
Share on FacebookShare on Twitter

1. This single-centred, observational cohort study demonstrated that among patients with head and neck cancer, a high neutrophil-lymphocyte ratio (NLR) was associated with worse overall survival and cancer-specific survival at three years compared to a low NLR.

2. High NLR was associated with worse T and N cancer staging and poorer performance status compared to low NLR.

Evidence Rating Level: 2 (Good)

Study Rundown: Given that inflammation is known to contribute to cancer progression, certain biomarkers can be utilized as a prognostication tool for solid tumours. Elevated neutrophil-lymphocyte ratio (NLR) is a poor prognostic marker for survival outcomes among patients with head and neck cancers in several studies. However, many of these studies have limitations and may not generalize to patients in the United States. This single-centred, observational cohort study examined the association of NLR and survival outcomes among nonmetastatic head and neck cancer patients who received chemoradiation. There were 496 patients included from April 2007 to March 2021. The primary outcomes were overall survival (OS) and cancer-specific survival (CSS). The threshold of NLR (high vs. low) was calculated to be 5.71 using maximum log-rank statistics. At 3 years, OS was 77.3% (95% CI: 73.1-81.7) versus 43.0% (95% CI: 30.6-60.3) and CSS was 83.4% (95% CI: 79.5-87.4) versus 55.6% (95% CI: 42.9-71.9) in the low and high NLR cohorts, respectively. As a result, Cox multivariable analysis demonstrated significantly worse OS (adjusted hazard ratio [aHR]: 1.97 [95% CI: 1.26-3.09]) and CSS (aHR: 2.33 [95% CI: 1.38-3.95]) in the high NLR cohort. Additionally, patients with higher T and N staging for their cancers were significantly more likely to have a high NLR. Patients noted to have a good performance status were less likely to have high NLR. Overall, this cohort study of patients with head and neck cancer who received chemoradiation demonstrated that high NLR was a negative prognostic factor, including poor survival outcomes, tumour staging, and performance status. This study was limited by its sample, which consisted mainly of White (87.1%) and male (82.9%) patients, reducing the generalizability of its findings.

Click to read the study in JAMA Network Open

Relevant Reading: Neutrophil-to-lymphocyte ratio in head and neck cancer prognosis: a systematic review and meta-analysis

RELATED REPORTS

Pembrolizumab improves survival in locally advanced head and neck cancer

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: head and neck cancerhead and neck squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)
Previous Post

Adjuvant antipsychotic use in children treated for depression may be associated with movement disorders

Next Post

Prenatal medication for opioid use disorder helps discharge infants back to mothers

RelatedReports

Elective neck dissection may be unnecessary for adenoid cystic carcinoma
Oncology

Pembrolizumab improves survival in locally advanced head and neck cancer

August 26, 2025
#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer
StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

July 18, 2025
#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

July 9, 2025
#VisualAbstract: Atezolizumab Does Not Improve Outcomes in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma
StudyGraphics

#VisualAbstract: Atezolizumab Does Not Improve Outcomes in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma

March 24, 2025
Next Post
Prenatal antidepressant exposure may increase risk of poor motor development

Prenatal medication for opioid use disorder helps discharge infants back to mothers

Nonpowder gun-related pediatric eye injuries on the rise

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

Medical vaccine exemptions increase after elimination of nonmedical exemptions

Vaccination leads to a small absolute risk for shoulder conditions

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cataract surgery is associated with increased incidence of diabetic retinopathy among patients with diabetes
  • 2MM: AI Roundup: FDA clears autonomous blood draw robot, UHS acquires Talkspace, Databricks reaches $190 billion valuation, and AI-designed glioblastoma vaccine advances
  • Aletta brings autonomous robotics into routine blood collection
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in